These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Renieramycin T Derivative DH_22 Induces p53-dependent Apoptosis in Lung Cancer Cells.
    Author: Anggraeni IG, Ei ZZ, Hotta D, Yokoya M, Chanvorachote P.
    Journal: In Vivo; 2023; 37(5):1960-1966. PubMed ID: 37652479.
    Abstract:
    BACKGROUND/AIM: Targeting apoptotic pathways has been identified as a promising strategy for the treatment of lung cancer. We synthesized a new derivative of renieramycin T (RT), named DH_22, and examined its anticancer activities in human lung cancer cells. MATERIALS AND METHODS: The RT derivative DH_22 was chemically modified from RT. The apoptosis-inducing effect was evaluated in A549 cells by annexin V-FITC/PI staining and nuclear staining assay (Hoechst/PI). In addition, the molecular pathway was analyzed by western blot analysis. RESULTS: In the cell viability and nuclear staining tests, DH_22 was discovered to be cytotoxic with an IC50 of 13.27 μM; it induced apoptosis of lung cancer cells. Regarding the mechanism, DH_22 contributed to the activation of p53-dependent apoptosis and decreased the cellular level of c-Myc. The p53-dependent mechanism was indicated by an increase in p53, an induction of the pro-apoptotic Bax protein, and a decrease in the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein. CONCLUSION: DH_22 has great potential for further development as a new anticancer drug.
    [Abstract] [Full Text] [Related] [New Search]